CJC-1295 No DAC + Ipamorelin vs CJC-1295 No DAC

The same relationship as the ipamorelin pairing, inverted. CJC-1295 No DAC is one of the two peptides inside the blend, sold on its own.

CJC-1295 No DAC — often written as modified GRF (1-29) — is a GHRH analogue without the drug-affinity complex, which is what "No DAC" records. Removing DAC removes the albumin-binding tail and with it the multi-day half-life; the unmodified molecule clears in minutes, and the published pharmacology describes a pulsatile signal rather than a sustained one. That distinction is routinely lost in how these compounds are written about elsewhere, and it is the reason the two versions are not interchangeable.

Adding ipamorelin adds a second, different upstream input: a selective ghrelin-receptor agonist rather than a GHRH one. The blend therefore addresses two receptor families from one vial. The single compound addresses one, and every reference behind it describes that one.

On price, the blend's premium over the single vial is in effect the ipamorelin — which is why the sensible comparison is the blend against both single vials together, not against either alone. The table above gives you the parts.

Both are lyophilised, stored at 2–8 °C, and hold 14 days refrigerated once reconstituted. We publish no claim that a two-receptor signal outperforms a one-receptor signal, because no controlled study of this blend exists to support one. Both are supplied for laboratory research only.